Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 98

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Efficacy and Safety of Daily Tadalafil in Men with Erectile Dysfunction Previously Unresponsive to On-Demand Tadalafil

McMahon, Chris·2004·The Journal of Sexual Medicine
DOI 10.1111/j.1743-6109.04042.x
Open this paper in CoChat — free account

Abstract

Objective: To assess the efficacy and safety of daily tadalafil, a potent selective phosphodiesterase 5 inhibitor, for the treatment of erectile dysfunction (ED) in men previously unresponsive to on-demand tadalafil. Materials and Methods: A total of 112 men with a mean age of 63 (range 21–79) and moderate to severe ED of various aetiologies were treated with tadalafil, taken on a daily basis at flexible daily doses of 10 and 20 mg for 12 weeks. The three primary outcomes were changes from the pretreatment and on-demand tadalafil baseline in the erectile function domain of the International Index of Erectile Function and the proportion of yes responses to questions 2 and 3 of the Sexual Encounter Profile. Additional efficacy instruments included a Global Assessment Question administered at completion of the study. Results: Compared with pretreatment and on-demand tadalafil baseline, daily dosed tadalafil significantly enhanced all efficacy outcome variables. Patients receiving daily tadalafil (10 mg) experienced a significant mean improvement of 12.8 and 8.2 in the International Index of Erectile Function erectile function domain score from baseline (P < 0.001) and from on-demand tadalafil, respectively (P < 0.001). Fifty-eight percent of intercourse attempts (Sexual Encounter Profile question 3) were successfully completed (P < 0.001 vs. pretreatment baseline, P < 0.001 vs. on-demand tadalafil). Improved erections at end point were reported by 69% of men compared with 42% of men with on-demand tadalafil. Daily tadalafil was well tolerated with headache, dyspepsia, and facial flushing as the most frequent adverse events. Conclusion: Daily tadalafil (10/20 mg) was effective and well tolerated in this study population and is an effective salvage for previous on-demand tadalafil nonresponders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1743-6109.04042.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 36

  1. Virag, 1985, Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men, Lancet, 1, 181, 10.1016/S0140-6736(85)92023-9 · DOI · Paper page
  2. Jensen, 1999, The prevalence and etiology of impotence in 101 male hypertensive outpatients, Am J Hypertens, 12, 271, 10.1016/S0895-7061(98)00225-8 · DOI
  3. Azadzoi, 1991, Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle, J Urol, 146, 238, 10.1016/S0022-5347(17)37759-5 · DOI
  4. Azadzoi, 1992, Erectile dysfunction due to atherosclerotic vascular disease: The development of an animal model, J Urol, 147, 1675, 10.1016/S0022-5347(17)37676-0 · DOI
  5. Saenz de Tejada, 1989, Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence, N Engl J Med, 320, 1025, 10.1056/NEJM198904203201601 · DOI
  6. Kaiser, 2004, Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease, J Am Coll Cardiol, 43, 179, 10.1016/j.jacc.2003.07.042 · DOI
  7. Brock, 2002, Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses, J Urol, 168, 1332, 10.1016/S0022-5347(05)64442-4 · DOI · Paper page
  8. Porst, 2003, Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial, Urology, 62, 121, 10.1016/S0090-4295(03)00359-5 · DOI · Paper page
  9. Atiemo, 2003, Salvage of sildenafil failures referred from primary care physicians, J Urol, 170, 2356, 10.1097/01.ju.0000096221.67967.ae · DOI
  10. McMahon, 2002, High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction, Int J Impot Res, 14, 533, 10.1038/sj.ijir.3900936 · DOI
  11. McMahon, 1999, Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy, J Urol, 162, 1992, 10.1016/S0022-5347(05)68085-8 · DOI
  12. Mydlo, 2000, Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy, Eur Urol, 38, 30, 10.1159/000020248 · DOI
  13. Saenz de Tejada, 2002, Effects of tadalafil on erectile dysfunction in men with diabetes, Diabetes Care, 25, 2159, 10.2337/diacare.25.12.2159 · DOI · Paper page
  14. Rendell, 1999, Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial, JAMA, 281, 421, 10.1001/jama.281.5.421 · DOI
  15. Stuckey, 2003, Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: Results of a randomized controlled trial, Diabetes Care, 26, 279, 10.2337/diacare.26.2.279 · DOI
  16. Goldstein, 2003, Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study, Diabetes Care, 26, 777, 10.2337/diacare.26.3.777 · DOI
  17. Emmick, 2002, Overview of the cardiovascular effects of tadalafil, Eur Heart J, 4, H32, 10.1016/S1520-765X(02)90050-7 · DOI
  18. Aranda, 2004, Erectile dysfunction in essential arterial hypertension and effects of sildenafil: Results of a Spanish national study, Am J Hypertens, 17, 139, 10.1016/j.amjhyper.2003.09.006 · DOI
  19. Steers, 1998, Sildenafil (Viagra) is effective in the treatment of severe male erectile dysfunction, Int J Impot Res, 10, S49
  20. Brock, 2003, Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy, J Urol, 170, 1278, 10.1097/01.ju.0000086947.00547.49 · DOI
  21. Lowentritt, 1999, Sildenafil citrate after radical retropubic prostatectomy, J Urol, 162, 1614, 10.1016/S0022-5347(05)68179-7 · DOI
  22. Hong, 1999, Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP), Int J Impot Res, 11, S15, 10.1038/sj.ijir.3900466 · DOI
  23. Anderson, 1991, Cardiovascular disease risk profiles, Am Heart J, 121, 293, 10.1016/0002-8703(91)90861-B · DOI · Paper page
  24. DeBusk, 2000, Management of sexual dysfunction in patients with cardiovascular disease: Recommendations of the Princeton Consensus Panel, Am J Cardiol, 86, 175, 10.1016/S0002-9149(00)00896-1 · DOI · Paper page
  25. El-Galley, 2001, Long-term efficacy of sildenafil and tachyphylaxis effect, J Urol, 166, 927, 10.1016/S0022-5347(05)65866-1 · DOI
  26. Steers, 2001, Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment, Int J Impot Res, 13, 261, 10.1038/sj.ijir.3900714 · DOI
  27. Moreland, 1999, Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor, Trends Endocrinol Metab, 10, 97, 10.1016/S1043-2760(98)00127-1 · DOI
  28. Gonzalez, 1999, Sildenafil causes a dose- and time-dependent downregulation of phosphodiesterase type 6 expression in the rat retina, Int J Impot Res, 11, S9, 10.1038/sj.ijir.3900465 · DOI
  29. Lin, 2002, Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters, Int J Impot Res, 14, 15, 10.1038/sj.ijir.3900802 · DOI
  30. Lin, 2003, Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism, J Urol, 170, S15, 10.1097/01.ju.0000075500.11519.e8 · DOI
  31. Ferrini, 2004, Long-term treatment with high doses of sildenafil does not up-regulate the levels of phosphodiesterase 5 (PDE5) in the rat penis, J Urol, 171, 424, 10.1016/S0022-5347(18)38816-5 · DOI
  32. Behr-Roussel, 2004, Chronic sildenafil enhances erectile responses and endothelium-dependent corporal relaxations of normal rats: Lack of tachyphylaxis, J Urol, 171, 425, 10.1016/S0022-5347(18)38819-0 · DOI
  33. Halcox, 2002, The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia, J Am Coll Cardiol, 40, 1232, 10.1016/S0735-1097(02)02139-3 · DOI · Paper page
  34. Desouza, 2002, Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes, Diabetes Care, 25, 1336, 10.2337/diacare.25.8.1336 · DOI
  35. Kimura, 2003, PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers, Hypertension, 41, 1106, 10.1161/01.HYP.0000068202.42431.CC · DOI
  36. Katz, 2000, Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure, J Am Coll Cardiol, 36, 845, 10.1016/S0735-1097(00)00790-7 · DOI · Paper page

Cited by

Metadata

Authors
McMahon, C.
Venue
The Journal of Sexual Medicine
Publisher
Oxford University Press (OUP)
Published
2004-11-01
Volume
1
Issue
3
Pages
292-300
ISSN
  • 1743-6109
  • 1743-6095
DOI
10.1111/j.1743-6109.04042.x
Cited by
98
References
5
Language
en
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.